Category: Featured Story

MesotheliomaCounsel has reported several times on the success Merck has had with its immunotherapy treatment Keytruda (pembrolizumab) in mesothelioma and lung cancer care. In addition, we have brought readers information on the benefits of Pfizer’s Xalkori (crizotinib) when treating lung cancer. Now, the two pharmaceutical giants are pairing up to combine the two treatments in …

Scientists and researchers continue to make strides in finding new approaches to treating the persistent and indefatigable mesothelioma. Chemotherapy, once considered the primary mode of treatment for the terminal cancer, is beginning to take a back seat to immunotherapy. A review of recent clinical trials shows success with immunotherapy where chemotherapy failed in small cell …

In August, MesotheliomaCounsel reported on the “spectacular” results melanoma patients achieved when treated with nivolumab (Opdivo), an immunotherapy drug. Now, a new study reports lung cancer patients realized a nearly three month survival benefit with the drug over another treatment. These promising results give mesothelioma patients in the U.S. hope they will see similar results. …